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Summary Mutation of the p53 protein may represent the commonest genetic event in human malignancy.
Abnormal p53 expression has been reported in a variety of carcinomas, sarcomas and lymphoid neoplasms;
however there is little information in relation to Hodgkin's disease. The expression of the nuclear phosphop-
rotein was investigated in paraffin-embedded biopsies from fifty patients with Hodgkin's disease using a
polyclonal antibody, CM-1 and in snap-frozen material with monoclonal antibodies, PAb 1801 and PAb 240.
Specifically, immunoreactivity was localised to the Reed-Sternberg cells or mononuclear variants in both
nodular sclerosing (86% cases) and mixed cellularity (57% cases) subtypes of Hodgkin's disease. However, no
positive staining was found in our cases of nodular lymphocyte predominant type Hodgkin's disease. Serial
biopsies following recurrence of disease demonstrated consistent results. It is suggested that overexpression of
p53, probably mutant, may have a role in the tumorigenesis of Hodgkin's disease.
Hodgkin's disease (HD) is perceived to be a malignant
disease of the lymphoid system. The natural history is that of
an inexorable progression towards death, survival rarely ex-
ceeding a few years. However, it is no longer a fatal condi-
tion. As many as 75% of all patients are curable by their
initial first line therapy. Investigations into the cell biology of
HD have been difficult due to naturally occurring factors.
One of the main obstacles is the relative paucity of Reed-
Sternberg cells (or variants), the presumed neoplastic compo-
nent of this condition, which often make up less than 1% of
the total cell number.
The p53 gene, located on the short arm of chromosome 17,
has been described as a tumour suppressor gene producing a
53 kD nuclear DNA-binding phosphoprotein (Levine et al.,
1991). It is thought that p53 has a role in the regulation of
the normal cell cycle (Kastan et al., 1991a), apoptosis
(Yonish-Rouach et al., 1991) and in response to DNA
damage (Kastan et al., 1991b). Several lines of evidence
support the notion that the loss of or alteration in p53 may
contribute to the deregulated growth characteristic of cancer
cells (Gaidano et al., 1991). Wild-type p53 can inhibit the
growth of human tumours containing p53 gene mutations
(Baker et al., 1990). Mutations within p53 genome are the
most common cancer-related genetic changes known at the
gene level (Vogelstein, 1990), found in a variety of malignan-
cies such as lung, colon, breast, liver, pancreas, sarcomas and
lymphoid conditions (See review by de Fromentel & Soussi,
1992).
Normal p53 is undetectable using standard immunocyto-
chemical techniques (Rodrigues et al., 1990). Overexpression
of p53 has recently been shown in numerous additional
human malignant tumours using a single monoclonal anti-
body (Porter et al., 1992). p53 staining has been shown in
Hodgkin's disease on formalin-fixed paraffin-embedded
material using PAb 1801 (Doglioni et al., 1991).
Using a polyclonal antibody particularly effective in
paraffins section, CM-1 (Bartkova et al., 1991; Barton et al.,
1991), along with PAbl801 (Banks et al., 1986) and PAb240
(Gannon et al., 1990), 55 biopsies from 50 patients with
Hodgkin's disease have been studied, confirming and exten-
ding the observation that the immunodetectable p53 may be
mutant within the Reed-Sternberg cells.
Material and methods
Tissue samples
Formalin-fixed paraffin-embedded blocks of 50 cases of HD
were retrieved from the histopathology files and snap-frozen
material from 12 cases from the tissue bank. All the patients
had been treated at St Bartholomew's Hospital and selected
on the basis of availability of suitable material. Sections from
a p53 positive colonic adenocarcinoma were used as positive
controls and normal tonsil or normal lymph nodes as
negative controls.
Immunohistochemnistry
Four micron paraffin sections were processed using the
avidin-biotin complex (ABC) method (Vectastatin Elite kit,
Vector, Burlingame, CA.) with diaminobenzidine tetrahyd-
rochloride as the chromogen (Guesdon et al., 1979). Sections
were incubated overnight at 4°C with CM-1 diluted 1 in 2000
in PBS. Snap-frozen material was sectioned and stained with
PAb 1801 or PAb 240 using the indirect immunoperoxidase
method (Filipe & Lake, eds, 1990, page 479).
Antibodies
The polyclonal CM-1 is a high-titre rabbit antiserum raised
against full-length recombinant human p53 (Bartkova et al.,
1991; Barton et al., 1991). It allows examination of formalin-
fixed, paraffin-embedded material and reacts with wild and
most mutant forms of the p53 protein.
PAb 1801 is a monoclonal antibody to human p53 that
recognises a denaturation-resistant epitope between amino
acids 32 and 79 (Banks et al., 1986). It identifies both human
wild-type p53 and some mutant forms but generally effective
on frozen material and methacarn-fixed tissue (Porter et al.,
1992).
PAb 240 recognises a denaturation-resistant epitope
located between amino acids 156 and 335. By immunoprecip-
itation it specifically detects mutant forms of p53 protein.
However, PAb 240 can also bind to denatured wild-type p53
(Gannon et al., 1990). Therefore its use in immunohisto-
chemistry does not differ from other antibodies, but is limited
to snap-frozen material.
Results
Fifty cases of Hodgkin's disease (36 nodular sclerosing, seven
mixed cellularity, five nodular lymphocyte predominant, one
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Figure I a CM-1 immunostaining of a case of nodular sclerosing Hodgkin's disease. Only scattered neoplastic cells are positive;
original magnification x 32. b CM-1 immunostaining of Reed-Stemnberg cells from the case in a. Strong nuclear staining is present
in most of the tumour cells. A single unstained RS cell is seen; original magnification x 256. c CM-I immunostaining of a case of
nodular lymphocyte predominant Hodgkin's disease showing the absence of staining in the L and H cells; original magnification
x 220. d CM-I immunostaining of Reed-Sternberg cells from a case of nodular sclerosing Hodgkin's disease demonstrating
heterogenous staining. Discordant staining of the nuclei of a binucleate RS cell is clearly shown (arrowed); original magnification
x 220.
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lymphocyte depleted and one case unclassified) were stained
with CM-1 on paraffin sections. In all subtypes except lym-
phocyte depleted and nodular lymphocyte predominant
(Figure Ic), Reed-Sternberg cells (RS cells) and mononuclear
variants (Hodgkin's cells) demonstrated nuclear staining
(Figures la and lb). The proportion of RS cells that are p53
positive in these cases varied between 10% and 60%. The
intensity of staining was variable within the same section as
well as between different sections but confined to the nuclei.
Occasionally a 'speckled' pattern of staining was seen in the
nucleus with nucleolar sparing. As illustrated in Figure Id,
heterogenous immunoreactivity was a consistent finding and
in rare instances discordant staining of the nuclei of
binucleate RS cells was seen.
Significant immunoreactivity was not seen in the surround-
ing lymphocytes. Sections of disease tissue processed in an
identical manner but without the addition of the primary
antibody were negative. The sections of normal tonsil and
normal lymph nodes remained consistently negative.
Snap-frozen sections from 12 of these cases demonstrated
similar results with the monoclonal antibodies. However, two
cases that produced positive staining with CM-I did not
demonstrate positive nuclear staining with PAb 240. This was
thought to be due to technical difficulties in using PAb 240
and snap-frozen material. Table I gives a summary of all the
results.
Multiple biopsies onfivepatients
In one patient a diagnosis of nodular sclerosing HD was
made on a peripheral lymph node biopsy and staging
laparotomy confirmed intra-abdominal nodal disease. CM-I
immunostaining was present in both biopsy samples.
In the other four patients, material from the initial presen-
tation and from a subsequent recurrence demonstrated con-
sistent results. One case (nodular sclerosing) remained CM-1
negative in both biopsies, while the remaining three cases
(two nodular sclerosing and one mixed cellularity) were
positive in all samples.
Discussion
Accumulation of the p53 protein is a common feature in
almost all human malignancies studied (de Fromentel &
Soussi, 1992). These results using the polyclonal antibody
CM-i indicate that p53 abnormalities also occur in Hodg-
kin's disease in up to 86% of cases. More specifically,
immunoreactivity was confined to the nuclei of Reed-
Sternberg cells and mononuclear variants. The two major
subtypes of HD showed similar results but the single case of
lymphocyte depleted HD did not reveal any positively staining
cells. The five cases ofnodular lymphocyte predominant (L &
H) Hodgkin's disease also did not demonstrate any CM-i
nuclear staining. This observation is in agreement with
previously published results (Doglioni et al., 1991).
Previously published reports on the immunohistochemistry
of p53 and these results support the notion that positive
immunostaining is restricted to malignant tumours. No
positive staining was seen in normal tissue or in the absence
of the primary antibody. p53 mutation and overexpression is
at present the most common genetic abnormality in the
Table I p53 immunohistochemical staining in Hodgkin's disease
Hodgkin's disease Number ofpositive cases (%)
Histological subtype CM-i PAb 240 PAb 1801
Nodular sclerosing 31/36 (86) 6/8 (75) 6/8 (75)
Mixed cellularity 4/7 (57) 3/4 (75) 2/4 (50)
Nodular lymphocyte predominant 0/5
Lymphocyte depleted 0/1
Unclassified 1/1
Totals 36/50 (72) 9/12 (75) 8/12 (67)
development of malignant tumours (Levine et al., 1991).
As in other malignancies such as colonic tumours, only a
proportion between 10% and 60% of presumed malignant
cells were positive. It is possible that this represents a clonal
expansion ofp53 mutant Reed-Sternberg cells as suggested in
some brain tumours (Sidransky et al., 1992) or perhaps
reflects a cell cycle dependance as recently shown in colorec-
tal tumours (Pignatelli et al., 1992). Doglioni et al. found a
smaller proportion (10-30%) of RS cells to be positive.
However, the main antibody employed was PAb 1801 which
is more effective on frozen sections and its use on formalin-
fixed paraffin-embedded tissue is not always successful
(Porter et al., 1992). The finding ofdiscordant staining of the
nuclei within the same Reed-Sternberg cell is most intriguing
and at present cannot be explained.
The absence of p53 staining in nodular lymphocyte
predominant (L & H) Hodgkin's disease is interesting in view
of the growing body of evidence that this is a form of low
grade B-cell lymphoma rather than being affiliated to the
other subtypes of HD (Pinkus & Said, 1985; Schmid et al.,
1991). This would be akin to the hypothesis that p53 changes
occur in malignant transformation from a dysplastic state
(van den Berg et al., 1989; Pignatelli et al., 1992) or transfor-
mation from a low grade to high grade tumour (Sidransky et
al., 1992).
There is evidence supporting a role for the Epstein-Barr
virus (EBV) in the aetiology of at least a proportion of cases
of HD. In situ hybridisation techniques have demonstrated
the presence of the EBV genome in the RS cells of 20-30%
cases (Weiss et al., 1989; Khan et al., 1992). Six from 30
cases in this study were previously shown to contain EBV
RNA in the RS cells (Khan et al., 1992). However, there was
no correlation with p53 positivity.
The histological nature of Hodgkin's disease with paucity
of abnormal cells within an admixture of essentially normal
cell types has given an opportunity to demonstrate the possi-
ble role of p53 in tumourigenesis. Positive immunoreactivity
confined to RS cells or their variants has been demonstrated
employing a polyclonal antibody CM-1 on paraffin embed-
ded tissue and monoclonal antibodies PAb 240 and 1801 on
snap-frozen samples. This endorses the view that Reed-
Sternberg cells (and variants) are the neoplastic components
of HD. There is further evidence towards the different nature
of the lymphocyte predominant nodular Hodgkin's disease
with the absence of positive p53 staining.
We would like to thank Dr Gordon Stamp for providing the CM-1,
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